Investment analysts at Needham & Company LLC began coverage on shares of Hologic (NASDAQ:HOLX) in a research report issued to clients and investors on Wednesday, TipRanks reports. The brokerage set a "buy" rating and a $64.00 price target on the medical equipment provider's stock. Needham & Company LLC's price target indicates a potential upside of 12.34% from the stock's current price.
A number of other research analysts also recently issued reports on the company. Stifel Nicolaus dropped their price target on Hologic from $52.00 to $45.00 and set a "hold" rating on the stock in a research note on Wednesday, April 8th. BTIG Research reiterated a "buy" rating and issued a $60.00 target price on shares of Hologic in a research note on Friday, June 26th. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Wednesday, April 8th. TheStreet upgraded Hologic from a "c+" rating to a "b-" rating in a research note on Thursday, May 14th. Finally, UBS Group lowered their target price on Hologic from $58.00 to $52.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 28th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of "Buy" and an average target price of $57.06.
NASDAQ:HOLX opened at $56.97 on Wednesday. The stock's 50 day moving average price is $52.80 and its 200 day moving average price is $48.91. The company has a market capitalization of $13.77 billion, a PE ratio of 24.88, a P/E/G ratio of 3.27 and a beta of 1.44. The company has a quick ratio of 1.04, a current ratio of 1.31 and a debt-to-equity ratio of 1.32. Hologic has a 52-week low of $26.49 and a 52-week high of $57.48.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, April 29th. The medical equipment provider reported $0.57 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.57. The firm had revenue of $756.10 million for the quarter, compared to the consensus estimate of $756.10 million. Hologic had a return on equity of 30.49% and a net margin of 18.53%. During the same quarter last year, the business posted $0.58 EPS. As a group, sell-side analysts anticipate that Hologic will post 2.32 EPS for the current fiscal year.
In related news, General Counsel John M. Griffin sold 4,906 shares of Hologic stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.00, for a total transaction of $245,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 190,996 shares of Hologic stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $50.97, for a total value of $9,735,066.12. The disclosure for this sale can be found here. Insiders sold a total of 238,345 shares of company stock valued at $12,185,194 over the last three months. Insiders own 1.00% of the company's stock.
A number of hedge funds have recently modified their holdings of the stock. Utah Retirement Systems raised its holdings in Hologic by 0.4% during the fourth quarter. Utah Retirement Systems now owns 50,759 shares of the medical equipment provider's stock worth $2,650,000 after purchasing an additional 200 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Hologic by 11.8% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,902 shares of the medical equipment provider's stock worth $99,000 after purchasing an additional 200 shares during the last quarter. Cutter & CO Brokerage Inc. raised its holdings in Hologic by 2.2% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 9,460 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 205 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in Hologic by 0.4% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 59,056 shares of the medical equipment provider's stock worth $3,083,000 after buying an additional 206 shares in the last quarter. Finally, Baird Financial Group Inc. increased its position in Hologic by 1.7% during the first quarter. Baird Financial Group Inc. now owns 14,831 shares of the medical equipment provider's stock worth $521,000 after buying an additional 242 shares in the last quarter. 92.45% of the stock is owned by hedge funds and other institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Recommended Story: Dividend Aristocrat Index
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 Stocks to Sell Now
Most people know that brokerage rankings are overstated because of pressure from publicly-traded companies. No investor relations person wants to see "hold" and "sell" ratings issued for their stock. In reality, a "buy" rating really means "hold." "Hold" ratings really mean "sell" and "sell" ratings mean get out while you still can.
If Wall Street's top analysts are consistently giving "hold" and "sell" ratings to a stock, you know there's a serious problem. We've compiled a list of the companies that Wall Street's top equities research analysts are consistently giving "hold" and "sell" ratings too. If you own one of these stocks, consider getting out while there's still time.
This slide show lists the 20 companies that have the lowest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "20 Stocks to Sell Now".